Farmacias Benavides S.A.B. de C.V. (BEVIDESB) fair value: what the stock is really worth
As of Jul 9, 2026: fair value of Farmacias Benavides S.A.B. de C.V. MXN 16.52, price MXN 25.00, upside -33.9%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Farmacias Benavides S.A.B. de C.V. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Farmacias Benavides, S.A.B. de C.V. engages in the retail of health and wellness products. The company also provides medicamentos, non-perishable food, and hygiene and beauty products, as well as photography. The company was founded in 1917 and is based in Monterrey, Mexico. Farmacias Benavides, S.A.B. de C.V.
Show more
Farmacias Benavides, S.A.B. de C.V. engages in the retail of health and wellness products. The company also provides medicamentos, non-perishable food, and hygiene and beauty products, as well as photography. The company was founded in 1917 and is based in Monterrey, Mexico. Farmacias Benavides, S.A.B. de C.V. operates as a subsidiary of Walgreens Boots Alliance, Inc.
Stock analysis
Farmacias Benavides S.A.B. de C.V. (BEVIDESB) currently trades at 25.00 MXN, while our model-based Fair Value estimate is 16.52 MXN, 33.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 31.66 MXN per share, and 11 of the 24 models we run sit above the 25.00 MXN price.
Bear case: the Economic Profit group reads lowest at 3.87 MXN, and 13 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 12.50 MXN (bear) to 20.65 MXN (bull), the price of 25.00 MXN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Farmacias Benavides S.A.B. de C.V. reported revenue of 17.2B MXN in FY2023 versus 13.9B MXN in FY2019, a compound +5.5%/yr. Reported net income was 282M MXN in FY2023.
Key figures
Market cap 10.2B MXN (≈ $563M) · P/E ratio 37.9 · P/S ratio 0.62 · EPS (TTM) 0.6600 MXN · Net margin 1.6% · Return on equity 59.8% · Return on assets (EBIT) 5.9% · Operating margin 5.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −34%, BEVIDESB screens richer than that median.
Fair Value models
Bear 12.50 MXNFair Value 16.52 MXNBull 20.65 MXN
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
’12
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.3% (2018) → 5.0% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Mexico: IMF forecast 3.3% a year to 2030, 4.8% from 2016 to 2025) that is about +7.0% a year for the price.
Compare Farmacias Benavides S.A.B. de C.V. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 56 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside−33.9% · Bottom 25%
Profitability
Return on equity (TTM)59.8% · Top 25%
Return on assets8.0% · Top 25%
Net margin (TTM)2.2% · Above median
Operating margin (TTM)5.1% · Above median
Growth and dividend
Revenue growth28.5% · Top 25%
Balance sheet
Debt / equity2.31× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (TTM)37.9× · Priciest 25%
P/B24.45× · Priciest 25%
P/S (TTM)0.49× · Cheaper than median
P/FCF15.5× · Priciest 25%
EV/EBITDA4.7× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 44
FUTURE (revenue growth)100· sector 18
PAST (return on equity)100· sector 22
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 65
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Farmacias Benavides S.A.B. de C.V. Fair Value". https://www.fairvalue-calculator.com/stock/BEVIDESB
Frequently asked questions
Is Farmacias Benavides S.A.B. de C.V. (BEVIDESB) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 16.52 MXN versus the last price from Jul 9, 2026 of 25.00 MXN, about −34% upside (overvalued).
What is the fair value of BEVIDESB?
Our model-based fair value for Farmacias Benavides S.A.B. de C.V. is 16.52 MXN (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 9, 2026): 25.00 MXN.
What is the quality score of BEVIDESB?
Farmacias Benavides S.A.B. de C.V. has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Our model-based price target is the fair value of 16.52 MXN (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 12.50 MXN, optimistic scenario 20.65 MXN. It is a calculation from audited fundamentals, not an analyst target.
What is the Farmacias Benavides S.A.B. de C.V. stock forecast for 2026?
Our models put fair value at 16.52 MXN, about −34% upside versus the last price from Jul 9, 2026 of 25.00 MXN (overvalued). Cautious scenario 12.50 MXN, optimistic scenario 20.65 MXN. The calculation is refreshed regularly with new filings.
What is the revenue of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Farmacias Benavides S.A.B. de C.V. reported trailing-twelve-month revenue of about 20.7B MXN (latest available figure, as of Sep 24, 2026).
What growth is priced into Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
For today's price to be fair in a discounted-cash-flow model, Farmacias Benavides S.A.B. de C.V. would have to grow free cash flow by +10.5 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BEVIDESB use?
Our models discount Farmacias Benavides S.A.B. de C.V. at 12.0 %: a base by market capitalisation (small), damped by beta 0.13, country premium for Mexico. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Farmacias Benavides S.A.B. de C.V. that is +10.5 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Farmacias Benavides S.A.B. de C.V. (BEVIDESB) delivered so far?
Over the past 5 years revenue at Farmacias Benavides S.A.B. de C.V. grew +4.5 % a year. The price currently implies +10.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Farmacias Benavides S.A.B. de C.V. (BEVIDESB) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into Farmacias Benavides S.A.B. de C.V. (+10.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The free-cash-flow yield on the price is 6.46 %: that much free cash flow Farmacias Benavides S.A.B. de C.V. produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Farmacias Benavides S.A.B. de C.V. it is 16.52 MXN per share (as of Sep 24, 2026), against a price of 25.00 MXN. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Farmacias Benavides S.A.B. de C.V. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BEVIDESB trades above its calculated fair value: price 25.00 MXN, fair value 16.52 MXN, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BEVIDESB?
No. The price is what the market pays today (25.00 MXN); the fair value is what the company's own numbers justify (16.52 MXN). For Farmacias Benavides S.A.B. de C.V. the two are 8.48 MXN per share apart. That gap is exactly why we show both numbers side by side.
How much is Farmacias Benavides S.A.B. de C.V. worth?
The market values Farmacias Benavides S.A.B. de C.V. at about 10.2B MXN (market capitalisation, as of Sep 24, 2026). Per share that is 25.00 MXN; our models calculate a fair value of 16.52 MXN per share.
What do the bullish and bearish scenarios say about BEVIDESB?
Our models span a range for Farmacias Benavides S.A.B. de C.V.: cautious scenario 12.50 MXN, base 16.52 MXN, optimistic 20.65 MXN per share (as of Sep 24, 2026, price 25.00 MXN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BEVIDESB?
Farmacias Benavides S.A.B. de C.V. trades at a price-to-earnings ratio of 37.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 16.52 MXN is built from several models across several years. Other multiples: P/B 24.5, P/S 0.5, EV/EBITDA 4.7.
How solid is the balance sheet of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Balance-sheet figures for Farmacias Benavides S.A.B. de C.V. (as of Sep 24, 2026): return on equity 59.8%, debt of 2.31 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is BEVIDESB from its 52-week high?
Farmacias Benavides S.A.B. de C.V. trades at 25.00 MXN, about 4% below its 52-week high of 26.00 MXN and at the low of 25.00 MXN (as of Jul 9, 2026). Distance from the high says nothing about value: that is what the fair value of 16.52 MXN is for.
Which stocks are comparable to Farmacias Benavides S.A.B. de C.V.?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Farmacias Benavides S.A.B. de C.V. stock attractive at the current price?
The data as of Sep 24, 2026: price 25.00 MXN, calculated fair value 16.52 MXN (−34%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BEVIDESB calculated?
We run Farmacias Benavides S.A.B. de C.V. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 16.52 MXN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Farmacias Benavides S.A.B. de C.V. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The latest price we hold is from Jul 9, 2026 and stands at 25.00 MXN. Our model-based fair value is 16.52 MXN, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Farmacias Benavides S.A.B. de C.V. right now?
The price sits above even our optimistic bull case (20.65 MXN). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Farmacias Benavides S.A.B. de C.V.
How large is the market capitalisation of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The market capitalisation of Farmacias Benavides S.A.B. de C.V. is 10.2B MXN (≈ $563M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The price-to-sales ratio of Farmacias Benavides S.A.B. de C.V. is 0.62 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Earnings per share at Farmacias Benavides S.A.B. de C.V. are 0.6600 MXN (price ÷ EPS = P/E 37.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The net margin of Farmacias Benavides S.A.B. de C.V. is 1.6% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The return on equity (ROE) of Farmacias Benavides S.A.B. de C.V. is 59.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
On an EBIT basis the return on assets of Farmacias Benavides S.A.B. de C.V. is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
The operating margin of Farmacias Benavides S.A.B. de C.V. is 5.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Revenue at Farmacias Benavides S.A.B. de C.V. is growing +28.5% versus a year earlier (3y avg +7.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Farmacias Benavides S.A.B. de C.V. (BEVIDESB)?
Earnings per share at Farmacias Benavides S.A.B. de C.V. are growing +14.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Farmacias Benavides S.A.B. de C.V. (BEVIDESB) carry?
The net debt of Farmacias Benavides S.A.B. de C.V. is 289M MXN (fiscal year 2023, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Farmacias Benavides S.A.B. de C.V. in the live analysis
One click puts Farmacias Benavides S.A.B. de C.V. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
